pantoprazole and Cardiovascular Diseases studies

Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."	9.14	Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
"It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin."	5.14	Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010)
" These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies."	2.90	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)
"Aspirin was discontinued and pantoprazole was started, with resolution of the bleeding."	2.49	Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature. ( Adly, G; Plakogiannis, R, 2013)

Research

Studies (8)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

All-cause Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	6 (75.00)	24.3611
2020's	1 (12.50)	2.80

Authors	Studies
Ma, Y	1
Li, S	1
Yang, H	1
Zhang, Y	1
Li, H	1
Zhou, L	1
Lin, J	1
Chen, Y	1
Hou, Y	1
Zhang, X	1
Liu, T	1
Zhou, X	1
Wang, Y	1
Moayyedi, P	2
Eikelboom, JW	2
Bosch, J	2
Connolly, SJ	2
Dyal, L	2
Shestakovska, O	2
Leong, D	2
Anand, SS	2
Störk, S	2
Branch, KRH	2
Bhatt, DL	2
Verhamme, PB	2
O'Donnell, M	2
Maggioni, AP	2
Lonn, EM	2
Piegas, LS	2
Ertl, G	2
Keltai, M	2
Cook Bruns, N	1
Muehlhofer, E	2
Dagenais, GR	2
Kim, JH	2
Hori, M	2
Steg, PG	2
Hart, RG	2
Diaz, R	2
Alings, M	2
Widimsky, P	2
Avezum, A	2
Probstfield, J	2
Zhu, J	2
Liang, Y	2
Lopez-Jaramillo, P	2
Kakkar, A	1
Parkhomenko, AN	2
Ryden, L	2
Pogosova, N	2
Dans, A	1
Lanas, F	2
Commerford, PJ	2
Torp-Pedersen, C	2
Guzik, T	1
Vinereanu, D	2
Tonkin, AM	2
Lewis, BS	2
Felix, C	2
Yusoff, K	2
Metsarinne, K	1
Fox, KAA	2
Yusuf, S	2
Bruns, NC	1
Kakkar, AK	1
Dans, AL	1
Guzik, TJ	1
Metsarinne, KP	1
Sung, JJ	1
Lau, JY	1
Ching, JY	1
Wu, JC	1
Lee, YT	1
Chiu, PW	1
Leung, VK	1
Wong, VW	1
Chan, FK	1
Juurlink, DN	1
Adly, G	1
Plakogiannis, R	1
Tincani, E	1
Bertoni, G	1
Silingardi, M	1
Ghirarduzzi, A	1
Bedogni, G	1
Iori, I	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048]	Phase 4	300 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
[NCT00153725]		156 participants	Interventional	2003-02-28	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Article	Year
Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults. Atherosclerosis, 2022, Volume: 358 Topics: Aged; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Histamine; Humans; Lansopra	2022
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding. Annals of internal medicine, 2010, Jan-05, Volume: 152, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster	2010
Clopidogrel with or without omeprazole in coronary disease. The New England journal of medicine, 2011, 02-17, Volume: 364, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cardiovascular Diseases; Chemistry, Pharmaceutical; Clopido	2011
Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients. The American journal of medicine, 2000, Volume: 108, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Amoxicillin; Anti-Ulcer Agents;	2000

pantoprazole and Cardiovascular Diseases